No Difference in Cerebral Glucose Metabolism in Patients With Alzheimer Disease and Differing Apolipoprotein E Genotypes

Abstract

The APOE epsilon 4 allele does not appear to be associated with specific deficits in brain metabolism in patients with AD despite evidence that the epsilon 4 allele is associated with preclinical alterations. This finding is consistent with previous epidemiologic results that have demonstrated a higher risk for AD in carriers of the epsilon 4 allele, but no change in the rate of progression of AD.